27 results
8-K
EVOK
Evoke Pharma Inc
11 May 23
Departure of Directors or Certain Officers
4:00pm
required a majority of our outstanding shares of common stock and, therefore, was not approved.
The approval of the Amendment to update the exculpation … of the Company as permitted by a recent amendment to Delaware law. The foregoing proposal required a majority of our outstanding shares of common stock
8-K
EVOK
Evoke Pharma Inc
13 Jan 21
Results of Operations and Financial Condition
4:02pm
gastroenterologists indicating an intent to prescribe GIMOTI, 94% indicated GIMOTI would be “appropriate” to use in moderate to severe patients.
A majority of each
8-K
EX-10.2
EVOK
Evoke Pharma Inc
11 May 23
Departure of Directors or Certain Officers
4:00pm
for election was previously so approved, cease for any reason to constitute a majority thereof; or
(c)The consummation by the Company (whether directly … , the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities
424B5
EVOK
Evoke Pharma Inc
13 Jan 21
Prospectus supplement for primary offering
4:34pm
the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock … adopted by a majority of our board of directors.
Requirements for Advance Notification of Stockholder Nominations and Proposals
Our amended
424B5
czs4 303m6o004
14 Jan 21
Prospectus supplement for primary offering
5:19pm
8-K
EX-10.1
cmyc3x
11 May 23
Departure of Directors or Certain Officers
4:00pm
8-K
EX-4.1
wqo1 9h5z2v2g9o
14 Feb 24
Unregistered Sales of Equity Securities
9:00am
424B4
txdl45g4y
9 Feb 24
Prospectus supplement with pricing info
5:14pm